We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Moderna, a clinical-stage biotechnology firm, has expanded its contract with the Biomedical Advanced Research and Development Authority (BARDA) to receive additional funding of up to $472m. The new
Novartis unveiled positive results from a Phase 3 study evaluating Jakavi (ruxolitinib) in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (GvHD). The Phase 3 study, dubbed REACH3,
Novavax has joined forces with FUJIFILM Diosynth Biotechnologies (FDB), a contract development and manufacturing organisation (CDMO), to produce bulk drug substance for its Covid-19 vaccine candidate NVX-CoV2373. The
Pfizer and BioNTech have signed an agreement with the US Department of Health and Human Services and the Department of Defence to supply their mRNA-based Covid-19 vaccine BNT162
Jazz Pharmaceuticals has received the US Food and Drug Administration (FDA) approval for Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution to treat cataplexy or excessive daytime
Gilead Sciences has agreed to acquire a 49.9% equity interest in Tizona Therapeutics, a clinical-stage developer of immunotherapies for cancers, for $300m. Along with the 49.9% stake, the
German pharmaceutical firm Grünenthal, through its US subsidiary Averitas Pharma, has received the US Food and Drug Administration (FDA) approval for QUTENZA (capsaicin) 8% patch to treat a
Pfizer and BioNTech reached an agreement with the UK Government to supply 30 million doses of their mRNA-based vaccine candidate against SARS-CoV-2, which causes Covid-19 disease. The companies
British pharmaceutical firm AstraZeneca has unveiled positive interim results from the Phase 1/2 COV001 trial of its potential Covid-19 vaccine AZD1222, licensed from the Oxford University. In the
GlaxoSmithKline (GSK) has agreed to acquire 10% stake in CureVac, and collaborate on research, development, manufacturing and commercialisation of mRNA-based vaccines and monoclonal antibodies (mAbs) against infectious diseases.